ETNB - Liver disease drug developers rise after Gilead-CymaBay M&A deal
2024-02-12 15:06:51 ET
More on CymaBay, Gilead, etc.
- Gilead Sciences: Cheap For A Reason
- Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript
- Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation
- Gilead to acquire CymaBay for $32.50/share in cash
- Gilead drops blood cancer candidate after high mortality risk